CO-1686 hydrobromide
CAS No. 1446700-26-0
CO-1686 hydrobromide( Rociletinib hydrobromide | AVL-301 hydrobromide | CNX-419 hydrobromide )
Catalog No. M11900 CAS No. 1446700-26-0
A potent, highly selective, irreversible inhibitor of mutant EGFR with Ki of 21.5 nM for EGFR L858R/T790M.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 50MG | 147 | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameCO-1686 hydrobromide
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, highly selective, irreversible inhibitor of mutant EGFR with Ki of 21.5 nM for EGFR L858R/T790M.
-
DescriptionA potent, highly selective, irreversible inhibitor of mutant EGFR with Ki of 21.5 nM for EGFR L858R/T790M; shows 22-fold selective over WT EGFR; EGFR del19, T790M, L858R/T790M and L858R mutant kinases demonstrates the highest degree of inhibition at 0.1 uM; orally bioavailable.Breast Cancer Phase 2 Clinical.
-
In VitroRociletinib (0.1 μM) inhibits EGFR potently and irreversibly, and inhibits more than 50% of 23 targets. Rociletinib potently and selectively inhibits growth of NSCLC cells expressing mutant EGFR and induces apoptosis. Rociletinib resistant NSCLC cell lines are sensitive to AKT inhibition.
-
In VivoRociletinib (100 mg/kg/day, p.o.) demonstrates anti-tumor activity in NSCLC EGFR mutant xenograft models. Rociletinib (50 mg/kg bid, p.o.) demonstrates anti-tumor activity in human EGFR-L858R and EGFR-L858R-T790M expressing transgenic mice.
-
SynonymsRociletinib hydrobromide | AVL-301 hydrobromide | CNX-419 hydrobromide
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR
-
Research AreaCancer
-
IndicationBreast Cancer
Chemical Information
-
CAS Number1446700-26-0
-
Formula Weight636.4634
-
Molecular FormulaC27H29BrF3N7O3
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 59 mg/mL
-
SMILESCC(=O)N1CCN(CC1)C2=CC(=C(C=C2)NC3=NC=C(C(=N3)NC4=CC(=CC=C4)NC(=O)C=C)C(F)(F)F)OC.Br
-
Chemical Name2-Propenamide, N-[3-[[2-[[4-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]phenyl]-, hydrobromide (1:1)
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Walter AO, et al. Cancer Discov. 2013 Dec;3(12):1404-15.
2. Tjin Tham Sjin R, et al. Mol Cancer Ther. 2014 Jun;13(6):1468-79.
3. Sequist LV, et al. N Engl J Med. 2015 Apr 30;372(18):1700-9.
molnova catalog
related products
-
Petosemtamab
Petosemtamab (MCLA 158) is a highly potent monoclonal antibody against EGFR (Kd: 0.22 nM) and LGR5 (Kd: 0.86 nM). Petosemtamab promotes EGFR signaling disruption and receptor breakdown in LGR5+ cancer cells.
-
Monastrol
Monastrol is a potent and cell-permeable inhibitor of the mitotic kinesin Eg5.
-
Afatinib dimaleate
An irreversible, dual EGFR/HER2 inhibitor with IC50 of 0.5/0.4/10/14 nM for wt EGFR/EGFR L858R/EGFR L858R+T790M/HER2 respectively.
Cart
sales@molnova.com